Dr. Carl Allen's primary research is focused on the clinical and biologic aspects of Langerhans cell histiocytosis (LCH). Along with Dr. Kenneth McClain, Dr. Carl Allen has developed the largest Histiocytosis Center in the world with over 100 new diagnoses annually, allowing the center to create a large bank of LCH tissues and plasma. Dr. Allen has developed gene expression and proteomic strategies to analyze the identity and function of the cells that cause LCH. The ultimate goal of these experiments is to identify genes, proteins, and pathways that may be used to diagnose and cure patients with LCH. These experiments may also provide insight into dendritic cell biology and tumor immunology. Dr. Carl Allen is an associate professor of pediatric hematology-oncology at Baylor College of Medicine (BCM). He is co-director of the Fayez Sarofim Lymphoma Program research laboratory at Texas Children's Cancer and Hematology Centers. Dr. Allen has significant experience in clinical as well as translational research. He is principal investigator of investigator-initiated clinical trials in Hodgkin lymphoma and non-Hodgkin lymphoma, both of which include correlative biology aims. He is national principal investigator of a study to optimize hematopoietic cell transplant in patients with EBV-related lymphoproliferative disorders, through the Blood and Marrow Transplant Clinical Trials Network. Dr. Allen has an ongoing collaborative research effort with the Uganda Cancer Institute research program, and collects tissue (viably preserved tumor, peripheral blood cells and plasma) and linked clinical data on approximately 25 new endemic Burkitt's Lymphoma cases every quarter from Uganda.
Publications/Creative Works
Click here to search for this faculty member's publications on PubMed.
Important Disclaimer: The responsibility for the accuracy of the information contained on these pages lies with the authors and user providing such information.